Skip to main content

Table 7 Univariate and multivariate analysis of factors predicting LRR in patients undergoing BCS after NAC

From: Factors affecting locoregional recurrence in breast cancer patients undergoing surgery following neoadjuvant treatment

Parameters

Univariate analysis

Multivariate analysis

 

LRR (n = 38)

No LRR (n = 394)

P value

Odds ratio

95% confidence interval

P value

Age (years)

  

0.661

   

50

25 (9.3%)

245 (90.7%)

 > 50

13 (8.0%)

149 (92.0%)

Clinical T stage

  

0.77

   

 T1

2 (8.0%)

23 (92.0%)

 T2

28 (8.5%)

302 (91.5%)

 T3

7 (12.1%)

51 (87.9%)

 T4

1 (5.3%)

18 (94.7%)

Clinical lymph node status

0.089

   

 N0

1 (1.7%)

57 (98.3%)

 N1

24 (9.1%)

239 (90.9%)

 N2

13 (11.7%)

98 (88.3%)

SBR grade

  

0.091

   

 1

1 (3.3%)

29 (96.7%)

 2

13 (8.0%)

150 (92.0%)

 3

23 (12.0%)

168 (88.0%)

 Unknown

1 (2.1%)

47 (97.9%)

Histologic type

  

0.127

   

 Invasive ductal carcinoma

36 (8.5%)

389 (91.5%)

 Invasive lobular carcinoma

1 (25.0%)

3 (75.0%)

 Mucinous carcinoma

0

1 (100.0%)

 Others

1 (50.0%)

1 (50.0%)

Margin

  

 > 0.999

   

 Free

36 (8.8)

371 (91.2%)

 Positive

2 (8.0%)

23 (92.0%)

ER

  

0.005

   

 Positive

14 (5.6%)

238 (94.4%)

 Negative

24 (13.3%)

156 (86.7%)

PR

  

0.004

   

 Positive

9 (4.5%)

190 (95.5%)

 Negative

29 (12.4%)

204 (87.6%)

HER2

  

0.151

   

 Positive

21 (11.0%)

170 (89.0%)

 Negative

17 (7.1%)

224 (92.9%)

Subtype

  

0.029

   

 HR + /HER2−

7 (4.6%)

146 (95.4%)

1

  

 HR + /HER2 + 

8 (7.5%)

99 (92.5%)

1.685

0.592–4.797

0.328

 HR-/HER2 + 

13 (15.5%)

71 (84.5%)

3.819

1.460–9.990

0.006

 HR−/HER2−

10 (11.4%)

78 (88.6%)

2.674

0.980–7.300

0.055

Neoadjuvant regimens

  

0.345

   

 Anthracycline only

2 (18.2%)

9 (81.8%)

 Taxane only

1 (2.6%)

37 (97.4%)

 Anthracycline + taxane

19 (8.5%)

204 (91.5%)

 Chemotherapy + target therapy

16 (10.0%)

144 (90.0%)

pCR

  

0.111

   

 Yes

8 (5.7%)

133 (94.3%)

 No

30 (10.3%)

261 (89.7%)

  1. ER estrogen receptor; HR hormone receptor; HER-2 human epidermal growth factor receptor 2; LRR locoregional recurrence; NAC neoadjuvant chemotherapy; pCR pathological complete response; PR progesterone receptor